Cited 0 times in
Increasing Prevalence of Group III Penicillin-Binding Protein 3 Mutations Conferring High-Level Resistance to Beta-Lactams Among Nontypeable Haemophilus influenzae Isolates from Children in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Han, MS | - |
dc.contributor.author | Jung, HJ | - |
dc.contributor.author | Lee, HJ | - |
dc.contributor.author | Choi, EH | - |
dc.date.accessioned | 2020-11-17T05:33:03Z | - |
dc.date.available | 2020-11-17T05:33:03Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 1076-6294 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/19143 | - |
dc.description.abstract | This study investigated the roles of beta-lactamase and penicillin-binding protein 3 (PBP3) alterations in the development of recent antimicrobial resistance in nontypeable Haemophilus influenzae (NTHi) isolated from Korean children. Nasopharyngeal NTHi isolates from children at a tertiary children's hospital were tested for antimicrobial susceptibility using E-test. beta-lactamase production was screened by the paper disc test, and polymerase chain reaction amplification of blaTEM and blaROB-1 was performed. The ftsI gene was amplified to identify PBP3 alteration. Of the 53 NTHi isolates, 69.8% were ampicillin nonsusceptible. The nonsusceptibility rates for cefaclor were 81.1%, cefpodoxime 69.8%, and amoxicillin/clavulanate 32.1%. About 60.3% and 32.1% of the isolates were genetically beta-lactamase-nonproducing ampicillin-resistant (gBLNAR) and genetically beta-lactamase-producing amoxicillin/clavulanate-resistant (gBLPACR) strains, respectively. Group III amino acid substitutions comprised 65.6% of the gBLNAR strains and 70.6% of the gBLPACR strains. MIC50 for amoxicillin/clavulanate, cefaclor, cefuroxime, cefpodoxime, and cefixime were more than 2-80 times higher in the gBLNAR and gBLPACR strains compared with gBLPAR strains. Group III gBLNAR strains had significantly higher ampicillin, amoxicillin/clavulanate, cefpodoxime, and cefixime minimum inhibitory concentrations than group II strains. Group III gBLNAR and gBLPACR NTHi strains are highly prevalent in Korea, raising the alarm about increasing beta-lactam resistance in NTHi. | - |
dc.language.iso | en | - |
dc.subject.MESH | Amino Acid Substitution | - |
dc.subject.MESH | Amoxicillin-Potassium Clavulanate Combination | - |
dc.subject.MESH | Ampicillin | - |
dc.subject.MESH | Ampicillin Resistance | - |
dc.subject.MESH | Anti-Bacterial Agents | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Haemophilus Infections | - |
dc.subject.MESH | Haemophilus influenzae | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Microbial Sensitivity Tests | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Penicillin-Binding Proteins | - |
dc.subject.MESH | Prevalence | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | beta-Lactam Resistance | - |
dc.subject.MESH | beta-Lactamases | - |
dc.subject.MESH | beta-Lactams | - |
dc.title | Increasing Prevalence of Group III Penicillin-Binding Protein 3 Mutations Conferring High-Level Resistance to Beta-Lactams Among Nontypeable Haemophilus influenzae Isolates from Children in Korea | - |
dc.type | Article | - |
dc.identifier.pmid | 30484742 | - |
dc.subject.keyword | antibiotic resistance | - |
dc.subject.keyword | beta-lactamase | - |
dc.subject.keyword | penicillin-binding protein | - |
dc.contributor.affiliatedAuthor | 정, 현주 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1089/mdr.2018.0342 | - |
dc.citation.title | Microbial drug resistance (Larchmont, N.Y.) | - |
dc.citation.volume | 25 | - |
dc.citation.number | 4 | - |
dc.citation.date | 2019 | - |
dc.citation.startPage | 567 | - |
dc.citation.endPage | 576 | - |
dc.identifier.bibliographicCitation | Microbial drug resistance (Larchmont, N.Y.), 25(4). : 567-576, 2019 | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.identifier.eissn | 1931-8448 | - |
dc.relation.journalid | J010766294 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.